Trinity Biotech plc / Fundamentals
Income statement
- Net revenue
€52.82M - Cost of goods sold
€34.87M - Gross profit
€17.94M - SG&A expenses
€24.27M - R&D expenses
€3.90M - EBITDA
-€14.50M - D&A
€1.60M - EBIT
-€18.18M - Interest expenses
€10.26M - EBT
-€26.37M - Tax expenses
€416.99K - Net income
-€27.27M
Cash flow statement
- Net deferred tax
€416.99K - Non-cash items
€15.44M - Changes in working capital
€5.31M - Operating cash flow
-€7.02M - Capex
€8.64M - Other investing cash flow
-€19.01M - Net investing cash flow
-€19.71M - Total cash dividends paid
€0.00 - Issuance of common stock
€6.57M - Debt repayment
€23.74M - Other financing cash flow
-€3.90M - Net financing cash flow
€28.14M - Foreign exchange effects
-€150.15K - Net change in cash
€1.27M - Cash at end of period
€4.43M - Free cash flow
€1.62M
Balance sheet
- Cash and cash equivalents
€4.43M - Cash and short-term investments
€4.43M - Total receivables
€12.53M - Inventory
€16.62M - Other current assets
€1.70M - Total current assets
€35.28M - Property, plant & equipment
€3.96M - Goodwill
€11.87M - Intangible assets
€32.18M - Long-term investments
€2.11M - Other non-current assets
€166.45K - Total non-current assets
€53.34M - Total assets
€88.62M - Accounts payable
€5.86M - Short-term debt
€2.14M - Other current liabilities
€18.49M - Total current liabilities
€27.54M - Long-term debt
€84.31M - Deferred tax liabilities
€3.91M - Other non-current liabilities
€3.04M - Total non-current liabilities
€91.27M - Total liabilities
€118.81M - Common stock
€3.60M - Retained earnings
-€67.88M - Other equity
-€4.67M - Total equity
-€30.19M - Total liabilities and shareholders' equity
€88.62M
Company information
- Market capitalization
€10.34M - Employees
380 - Enterprise Value
€106.72M
Company ratios
- Gross margin
-
34.0% Worse than peer group: 47.2% - EBITDA margin
-
-27.5% Much better than peer group: -1,306.0% - EBIT margin
-
-34.4% Much better than peer group: -1,405.5% - EBT margin
-
-49.9% Much better than peer group: -1,390.1% - Net margin
-
-51.6% Much better than peer group: -1,388.7% - ROE
-
90.4% Much better than peer group: -15.8% - ROA
-
-30.8% Worse than peer group: -18.0% - Asset turnover
-
59.6% Even with peer group: 58.3% - FCF margin
-
-29.6% Much better than peer group: -1,128.9% - FCF yield
-151.4% - Efficiency ratio
127.5% - Net sales per employee
-
€138.99K - Net income per employee
-
-€71.78K